ABCL NASDAQ
AbCellera Biologics Inc.
1W: +1.3%
1M: -4.9%
3M: +128.4%
YTD: +252.2%
1Y: +111.6%
3Y: +181.6%
5Y: -20.9%
$12.83
+0.75 (+6.21%)
After Hours: $12.87 (+0.04, +0.31%)
Weekly Expected Move ±10.2%
$9
$11
$12
$13
$14
Credit Risk of going bust: higher than 55% of companies Debt: 3.3% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.07 (down 99.5%), AbCellera Biologics Inc. would be worth roughly what it owes.
Total debt $135.6M against a stock market value of $3.91B.
Distance to default 4.65 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $67.8M (short-term plus half of long-term), stock volatility 82.8%; Altman Z'' 4.07. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $135.6M against a stock market value of $3.91B.
Distance to default 4.65 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $67.8M (short-term plus half of long-term), stock volatility 82.8%; Altman Z'' 4.07. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider+$1.6M
Congress—
ETF Holdings—
Key Statistics
Market Cap$4.2B
52W Range2.745-15.02
Volume3,452,961
Avg Volume6,763,580
Beta1.19
Dividend—
Analyst Ratings
Company Info
CEOCarl Hansen
Employees562
SectorHealthcare
IndustryBiotechnology
IPO Date2020-12-11
Websiteabcellera.com
150 W 4th Ave
Vancouver, BC V5Y 1G6
CA
Vancouver, BC V5Y 1G6
CA
604 559 9005
About AbCellera Biologics Inc.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Latest News
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of “Moderate Buy” from Analysts
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
Abcellera Biologics stock hits 52-week high at 12.58 USD By Investing.com - Investing.com Canada
How (ABCL) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Hayden Michael R | P-Purchase | 53,613 | $10.64 | 2026-08-24 |
| Montalbano John S. | P-Purchase | 10,000 | $11.03 | 2026-08-18 |
| Booth Andrew | P-Purchase | 37,200 | $10.32 | 2026-08-14 |
| Hayden Michael R | P-Purchase | 46,387 | $10.37 | 2026-08-12 |
| Hayden Michael R | G-Gift | 50,000 | — | 2026-08-11 |